Financials

%ChgLast 12MReverse

	FY202312/31/2023	FY202412/31/2024	FY202512/31/2025	Last 12M03/31/2026
Cash and Cash Equivalents	696.1	543.1	383.7	440.9
Short Term Investments	1,156.8	1,746.2	1,641.9	1,467.1
Cash and Short Term Investments	1,853.0	2,289.3	2,025.7	1,908.1
Net Receivables	1.3	-	-	-
Inventory	-	-	-	-
Other Current Assets	25.1	38.3	49.4	59.8
Total Current Assets	1,879.3	2,327.6	2,075.0	1,967.9
Property, Plant & Equipment	100.0	141.8	165.3	161.4
Long Term Investments	-	-	-	-
Other Non-Current Assets	10.1	17.6	43.8	54.0
Total Non-Current Assets	182.4	230.7	279.5	285.8
Total Assets	2,061.7	2,558.3	2,354.5	2,253.7
Account Payables	61.8	54.4	64.6	80.5
Short Term Debt	-	-	-	-
Deferred Revenue	-	-	-	-
Other Current Liabilities	27.5	31.4	66.1	26.5
Total Current Liabilities	143.9	163.9	290.4	289.6
Long Term Debt	-	-	142.2	280.6
Other Non-Current Liabilities	8.0	3.9	288.2	41.2
Total Non-Current Liabilities	91.7	129.2	432.8	464.2
Total Liabilities	235.5	293.1	723.2	753.8
Common Stock	0.0	0.0	0.0	0.0
Retained Earnings	-1,137.7	-1,737.8	-2,869.1	-3,322.9
Total Stockholders Equity	1,826.2	2,265.2	1,631.3	1,499.9
Total Liabilities and Equity	2,061.7	2,558.3	2,354.5	2,253.7

Revolution Medicines, Inc.(RVMD US)